Form 8-K - Current report:
SEC Accession No. 0001104659-24-114097
Filing Date
2024-11-05
Accepted
2024-11-05 07:08:41
Documents
15
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2427419d1_8k.htm   iXBRL 8-K 23850
2 EXHIBIT 99.1 tm2427419d1_ex99-1.htm EX-99.1 60794
6 GRAPHIC image_001.jpg GRAPHIC 5662
  Complete submission text file 0001104659-24-114097.txt   273771

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvct-20241105.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20241105_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20241105_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2427419d1_8k_htm.xml XML 3652
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 241425604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)